A Study for Patients With Non-Hodgkin's Lymphomas

A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas

In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes:

• T-cell lymphoma: Peripheral and Cutaneous T-cell lymphoma (PTCL, CTCL)
• Indolent B-cell lymphoma: Small lymphocytic lymphoma, follicular lymphoma (Gr 1 or 2) and marginal zone lymphoma
• Aggressive B-cell lymphoma: Primary CNS lymphoma, follicular lymphoma (Gr 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma.

Inclusion Criteria:

• Have measurable lesions
• Have recovered from prior chemotherapies
• Have an estimated life expectancy of at least 12 weeks
• Hepatic: total bilirubin less than or equal to 1.5 XULN; ATL/AST less than or equal to 2.0 x ULN (less than 5x if liver metastases are present)
• Renal: serum creatinine less than or equal to 1.5XULN
• Adequate bone marrow reserve: platelets greater than or equal to 75 x 109 /Liter (L) Criteria:
• Have a second primary malignancy (except adequately treated nonmelanomatous skin cancer, or other cancer that is considered cured by surgical resection or radiation).
• Anti-lymphoma therapy within the past 3 weeks
• Unable to swallow tablets
• Unable to discontinue use of carbamazepine, phenobarbital and phenytoin at least 14 days prior to study enrollment